A biotechnology company specializing in the detailed structural analysis of complex mixture drugs of the development of generic or biosimilar versions of complex drug products as well as to the discovery and development of novel drugs.


Updates from The Motley Fool

Latest updates on Momenta Pharmaceuticals from Fool.com.  The Fool has written over 100 articles on Momenta Pharmaceuticals.
Momenta Blocked

Novartis, the biotech's partner on Glatopa, is having trouble capturing more of the Copaxone market.

Our Best Predictions in 2015

Motley Fool contributors share with investors some of their top-performing predictions from the p...

Momenta Slowed (Temporarily)

Momenta Pharmaceuticals, Inc. reports a quarter-over-quarter decrease in revenue from sales of Gl...



Stock Performance

View Interactive MNTA Charts
Sponsored by

Key Data Points

Primary metrics and data points about Momenta Pharmaceuticals.
Current Price: $14.05
Prev Close: $14.20
Open: $14.25
Bid: $14.00
Ask: $15.70
Day's Range: $14.00 - $14.28
52wk Range: $10.75 - $19.90
Volume: 518,798
Avg Vol 1,122,156
Market Cap: $1B
P/E (ttm): -23.28
EPS (ttm): ($0.61)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Momenta Pharmaceuticals.
CAPS Rating 3 out of 5
 
430 Outperform
30 Underperform
CAPS All Stars
 
105 Outperform
7 Underperform

How do you think Momenta Pharmaceuticals will perform against the market?



You pick for Momenta Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Craig A. Wheeler, CEO

98% Approve

Based on 20 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Momenta Pharmaceuticals.

A biotechnology company specializing in the detailed structural analysis of complex mixture drugs of the development of generic or biosimilar versions of complex drug products as well as to the discovery and development of novel drugs.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers